Technology company Tempus AI Inc (NASDAQ:TEM) on Thursday announced an expanded multi-year collaboration with biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) to support the development of Gilead's oncology pipeline.

The agreement builds on prior use of Tempus' de-identified multimodal data to inform oncology research and development initiatives.

Gilead has previously applied Tempus' datasets to areas including clinical trial design, indication selection, biomarker strategy, health outcomes analysis, and real-world evidence generation. Under the expanded arrangement, Gilead will gain enterprise-wide access to Tempus' AI-driven Lens platform. The broader access is designed to enable integration of larger datasets across multiple indications alongside dedicated analytical services from Tempus.

Leaders from both companies emphasised the role of combining scientific expertise with real-world data insights to improve clinical decision-making and support cancer care outcomes.